Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 92Polycystic Ovary Syndrome 11Neoplasm Metastasis 7Infertility 5Carcinoma, Ductal, Breast 5Carcinoma, Lobular 4Osteoporosis 3Neoplasms, Hormone-Dependent 3Neoplasms 3Breast Neoplasms, Male 3Advanced Breast Cancer 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Carcinoma In Situ 2Bone Diseases, Metabolic 2Unilateral Breast Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Osteitis Deformans 1Obesity 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1Infertility, Female 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Hereditary Breast and Ovarian Cancer Syndrome 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1

Interventions

spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Trastuzumab 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2+ Breast Cancer × Letrozole × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡